Magia diagnostics Revenue and Competitors

MagIA diagnostics was founded in 2017 and is based in Grenoble (France). We have developed a highly innovative and generic technology allowing for easy transfer of any immunoassay onto our portable system. Based on our patented generic no-wash immunoassay technique emerging from 15 years of research, MagIA diagnostics unique value proposition is to bring lab immunoassays directly to the patient. The growing challenges of pandemic risk management and personalised health approaches drive the need for decentralised diagnostic solutions. MagIA Diagnostics' highly sensitive infectious disease screening platform integrates a multi-parameter lab-performant immuno-analysis on a single disposable chip. We develop a unique panel of infectious diseases assay chips, starting with a Hepatitis B and a combined HIV / Hepatitis screening panel to enhance access to care. At MagIA diagnostics, we believe in accessible Point-of-Care diagnostics. To make it available to everyone, we are also developing a business-to-business approach: as companies providing immunologic diagnostic solutions (14B$ human immunodiagnostic market) are pushing to bring their products closer to the patients, we offer them access to our generic Point-of-Care platform. It preserves the laboratory sensitivity while significantly reducing test time (15 min) and sample volume (5 - 10 µl), offering a unique and highly relevant solution for all immunoassay applications.